Marine natural products as anticancer drugs
Citations
4,649 citations
1,262 citations
623 citations
Cites background from "Marine natural products as anticanc..."
...Neovastat inhibits the binding of VEGF to its receptor [19,20]....
[...]
...salinosporamide hat inhibits proteasome or neovastat that blocks the vascular ndothelial growth factor (VEGF) binding to its receptor) [19,20]....
[...]
...[19] Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH....
[...]
617 citations
Cites background from "Marine natural products as anticanc..."
...This area of research, which is continually expanding and is of enormous current interest, explores new natural products coming from different sources, among which the sea could be quoted as an almost infinite source of resources [12–19], with a view to collecting more potent, more selective and less toxic compounds than today’s drugs, and hence with better therapeutic indices....
[...]
536 citations
References
4,210 citations
"Marine natural products as anticanc..." refers background in this paper
...By contrast, open ocean waters are generally low in nutrients and have been likened to deserts in terms of biomass and species diversity, although recent evidence suggests the existence of substantial microbial diversity in pelagic waters (1)....
[...]
2,985 citations
"Marine natural products as anticanc..." refers background in this paper
...This has occurred in part during a period of some retrenchment in the field of natural products in general and may cause some to rethink the wisdom of prematurely departing from this highly productive pursuit (4)....
[...]
705 citations
"Marine natural products as anticanc..." refers background in this paper
...Therefore, current clinical evaluation of LU-103793 has been discontinued (53)....
[...]
...Phase II clinical trials in the United States and Europe continue for ovarian, STS, endometrial, breast, prostate, and non–small cell lung cancer, with notable recent success in combination drug therapy (53)....
[...]
...Large-scale collections, aquaculture and synthetic efforts have all been employed (53), and culminated in the development of a semisynthesis of ET-743 from cyanosafracin B (Fig....
[...]
...ILX-651 is currently in three phase II clinical trials for patients with locally advanced or metastatic non–small cell lung cancer and patients with hormone-refractory prostate cancer previously treated with Docetaxel (53).3 Results of a phase II study where ILX-651 was given daily for five consecutive days on a three week schedule in patients with inoperable locally advanced or metastatic melanoma indicate that it is ‘‘a safe, well-tolerated treatment for locally advanced and metastatic melanoma patients’’ (54)....
[...]
...The multifaceted mechanism of action of ET-743 includes interference with the cellular transcription-coupled nucleotide excision repair to induce cell death and cytotoxicity which is independent of p53 status yet occurs with multidrug resistance elicitation (53, 59)....
[...]
624 citations